Trial Profile
A Phase II clinical trial investigating AAV-REP1 gene therapy for the treatment of choroideremia (CHM)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2019
Price :
$35
*
At a glance
- Drugs Timrepigine emparvovec (Primary)
- Indications Choroideraemia
- Focus Therapeutic Use
- 07 Jun 2019 According to a Biogen media release, the company has acquired Nightstar Therapeuitcs.
- 06 Feb 2016 New trial record